Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients
| Title: | Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients |
|---|---|
| Authors: | Cristina Maccalli, Diana Giannarelli, Carla Chiarucci, Ornella Cutaia, Gianluca Giacobini, Wouter Hendrickx, Giovanni Amato, Diego Annesi, Davide Bedognetti, Maresa Altomonte, Riccardo Danielli, Luana Calabrò, Anna Maria Di Giacomo, Francesco M. Marincola, Giorgio Parmiani, Michele Maio |
| Source: | OncoImmunology, Vol 6, Iss 7 (2017) |
| Publisher Information: | Taylor & Francis Group, 2017. |
| Publication Year: | 2017 |
| Collection: | LCC:Immunologic diseases. Allergy LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | cytotoxic t-lymphocyte antigen-4 (ctla-4), metastatic melanoma, nkg2d ligands, programmed cell death-1 (pd-1), t cell responses, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | The introduction of immune checkpoint blockade into the clinical practice resulted in improvement of survival of a significant portion of melanoma patients. Consequently, predictive biomarkers of response are needed to optimize patient's stratification and the development of combination therapies. The aim of this study was to determine whether levels of soluble NKG2D ligands (MICA, MICB, ULBP1, 2 and 3; sNKG2DLs) in the serum of melanoma patients can serve as useful predictors of response to the treatment with immune checkpoint blockade. sNKG2DLs were measured by ELISA in baseline and post-treatment serum and these results were correlated with the clinical outcome of melanoma patients (N = 194). The same determinations were performed also in a cohort of patients (N = 65) treated with either chemotherapy, radiotherapy, or mutated BRAF inhibitors (BRAFi). Absence of soluble MICB and ULBP-1 in baseline serum correlated with improved survival (OS = 21.6 and 25.3 mo and p = 0.02 and 0.01, respectively) of patients treated with immunological therapies while detectable levels of these molecules were found in poor survivors (OS = 8.8 and 12.1 mo, respectively). Multivariate analysis showed that LDH (p |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2162-402X 2162402X |
| Relation: | https://doaj.org/toc/2162-402X |
| DOI: | 10.1080/2162402X.2017.1323618 |
| Access URL: | https://doaj.org/article/05691ff539e94d23badce601a4beb680 |
| Accession Number: | edsdoj.05691ff539e94d23badce601a4beb680 |
| Database: | Directory of Open Access Journals |
| ISSN: | 2162402X |
|---|---|
| DOI: | 10.1080/2162402X.2017.1323618 |
| Published in: | OncoImmunology |
| Language: | English |